Patents Assigned to Secretary of State for Health and Social Care
-
Patent number: 11938180Abstract: The invention provides poliovirus like particles, which comprise stabilised empty poliovirus capsids that retain their native antigenic properties. The invention also provides methods of identifying mutations useful in the production of such poliovirus like particles, methods of producing such poliovirus like particles and the use of such poliovirus like particles in methods of vaccinating against poliovirus.Type: GrantFiled: January 17, 2018Date of Patent: March 26, 2024Assignee: SECRETARY OF STATE FOR HEALTH AND SOCIAL CARE, MINISTERIAL CORRESPONDENCE AND PUBLIC ENQUIRIES, DEPARTMENT OF HEALTH AND SOCIAL CAREInventor: Andrew Macadam
-
Patent number: 11746116Abstract: The invention relates to antibiotic compounds of formula (A1) and pharmaceutically acceptable salts, solvates, tautomers and combinations thereof, wherein X and L are optional linkers and one of RA or R1 comprises Ar1, wherein Ar1 is an antibiotic resistance breaker moiety which comprises an optionally substituted C6-10 aryl, C7-13 aralkyl, C5-10 heteroaryl, C6-13 heteroaralkyl, C5-10 heterocyclyl, C6-13 heterocyclalkyl, C3-10 carbocyclyl, C4-13 carbocyclalkyl, —C(?NR?)—NR?R? or —CH2—CH?CH2 group; wherein after administration of the compound to a bacterial infection this moiety reduces or prevents efflux. The invention also discloses pharmaceutical compositions comprising compounds of formula (A1) and the use of such compounds as medicaments, in particular, to treat bacterial infections, such as drug-resistant bacterial infections.Type: GrantFiled: May 30, 2018Date of Patent: September 5, 2023Assignees: King's College London, Secretary of State for Health and Social CareInventors: Khondaker Mirazur Rahman, Shirin Jamshidi, Mark Benjamin Laws, Kazi Nahar, John Mark Sutton, Charlotte Hind
-
Publication number: 20230165949Abstract: The present application relates to recombinant Clostridium difficile antigens based on a fusion protein that consists of or comprises a first amino acid sequence and a second amino acid sequence, wherein: a) the first amino acid sequence is provided by an amino acid sequence that has at least 80% sequence identity with an amino acid sequence consisting of residues 1500-1850 of a C. difficile Toxin A sequence or residues 1500-1851 of a C. difficile Toxin B sequence; and b) the second amino acid sequence is provided by an amino acid sequence that has at least 80% sequence identity with an amino acid sequence consisting of a long repeat unit located within amino acid residues 1851-2710 of a C. difficile Toxin A sequence or within amino acid residues 1852-2366 of a C. difficile Toxin B sequence; though with the proviso that the fusion protein is not a polypeptide comprising amino acid residues 543-2710 of a C.Type: ApplicationFiled: August 23, 2022Publication date: June 1, 2023Applicants: Secretary of State for Health and Social Care, MicroPharm LimitedInventors: Clifford Shone, April Roberts, Helen Ahern, Michael Maynard-Smith, John Landon
-
Publication number: 20230140713Abstract: Methods are presented which use impedance flow cytometry for rapid susceptibility testing of antimicrobial agents including phage, antimicrobial peptides and rapid analysis of antimicrobial mediated serum bactericidal assays.Type: ApplicationFiled: March 19, 2021Publication date: May 4, 2023Applicants: SECRETARY OF STATE FOR HEALTH AND SOCIAL CARE, THE UNIVERSITY OF SOUTHAMPTONInventors: John Mark Sutton, Charlotte Hind, Hywel Morgan, Daniel Spencer
-
Publication number: 20220275346Abstract: The present invention provides a viral vector or bacterial vector, said vector comprising a nucleic acid sequence encoding a Hantavirus nucleoprotein or antigenic fragment thereof; wherein said vector is capable of inducing a protective immune response in a subject. The present invention also provides compositions and uses of the vector in methods of medical treatment.Type: ApplicationFiled: July 29, 2020Publication date: September 1, 2022Applicant: SECRETARY OF STATE FOR HEALTH AND SOCIAL CAREInventors: Roger Hewson, Stuart Dowall, Emma Kennedy, Miles Carroll
-
Publication number: 20210369830Abstract: The present application relates to recombinant Clostridium difficile antigens based on a fusion protein that consists of or comprises a first amino acid sequence and a second amino acid sequence, wherein: a) the first amino acid sequence is provided by an amino acid sequence that has at least 80% sequence identity with an amino acid sequence consisting of residues 1500-1850 of a C. difficile Toxin A sequence or residues 1500-1851 of a C. difficile Toxin B sequence; and b) the second amino acid sequence is provided by an amino acid sequence that has at least 80% sequence identity with an amino acid sequence consisting of a long repeat unit located within amino acid residues 1851-2710 of a C. difficile Toxin A sequence or within amino acid residues 1852-2366 of a C. difficile Toxin B sequence; though with the proviso that the fusion protein is not a polypeptide comprising amino acid residues 543-2710 of a C.Type: ApplicationFiled: April 7, 2021Publication date: December 2, 2021Applicants: Secretary of State for Health and Social Care, MicroPharm LimitedInventors: Clifford Shone, April Roberts, Helen Ahern, Michael Maynard-Smith, John Landon
-
Publication number: 20210230710Abstract: The present invention is directed to a method for detecting the presence or absence of an antiviral drug-resistant HSV, comprising: (a) identifying one or more HSV mutation selected from: (i) a thymidine kinase (TK) mutation selected from 250G>A (HSV-2), 0C>T (HSV-1), 268C>T (HSV-2), 373C>T (HSV-1), 146T>G (HSV-1), 363G>A (HSV-), 497T>A (HSV-1), 558G>T (HSV-2), 641A>G (HSV-2), 715T>C (HSV-1), 938T>C(HSV-2), 437_438insA (HSV-1), 169delC (HSV-1), 170delC (HSV-1), 171delC (HSV-1), 1072delC (HSV-1), 458delC (HSV-2), 459delC (HSV-2), 460delC (HSV-2), 461delC (HSV-2), 881delC (HSV-1), 882delC (HSV-1), 883delC (HSV-1), 884delC (HSV-1), and 885delC (HSV-1); and (ii) a DNA polymerase (DNA pol) mutation selected from 1882C>G(HSV-2), 2405T>G (HSV-1), 2500G>T (HSV-1), 2515A>G (HSV-1), 2892_2893insT(HSV-1), 2893_2894insT (HSV-1), 2894_2895insT (HSV-1), and 2895_2896insT (HSV-1); wherein the presence of said one or more HSV mutation confirms the presence of an antiviral drug-resType: ApplicationFiled: June 4, 2019Publication date: July 29, 2021Applicant: Secretary of State for Health and Social CareInventor: Jean Lutamyo Mbisa
-
Publication number: 20210222118Abstract: The present invention provides in vitro methods for culturing Legionella, comprising incubating a Legionella bacterium on a charcoal-free solid agar medium comprising: serum, wherein the serum is present at a concentration of 1%-35% (v/v); a nitrogen source; and an iron source. Charcoal-free solid agar media for use in methods of the invention are also provided.Type: ApplicationFiled: August 23, 2019Publication date: July 22, 2021Applicant: SECRETARY OF STATE FOR HEALTH AND SOCIAL CAREInventors: Victoria Jane Chalker, Owen Brad Spiller, Edward Portal
-
Patent number: 11021534Abstract: The present invention provides an antigenic composition for use as a mycobacterial vaccine, said composition comprising (i) a first mycobacterial antigenic polypeptide, wherein said first mycobacterial antigenic polypeptide comprises a polypeptide sequence having at least 70% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 6, 12, 2, 18, 8, 10, 16, 4, or a fragment thereof having at least 50 consecutive amino acids thereof; or (ii) a first mycobacterial polynucleotide, wherein said first mycobacterial polynucleotide comprises a polynucleotide sequence encoding said first mycobacterial antigenic polypeptide, or wherein said first mycobacterial polynucleotide comprises a polynucleotide sequence selected from SEQ ID NO: 5, 11, 1, 17, 7, 9, 15, 3.Type: GrantFiled: August 8, 2017Date of Patent: June 1, 2021Assignee: SECRETARY OF STATE FOR HEALTH AND SOCIAL CAREInventors: Yper Hall, Joanna Bacon, Philip Marsh
-
Patent number: 10967045Abstract: A composition is provided comprising N. meningitidis outer membrane vesicles, wherein said outer membrane vesicles are enriched with at least one antigenic component. The composition is suitable for use in vaccines and for treatment of infection, particularly meningococcal infection, demonstrating a broad spectrum of protection. A number of preferred antigenic components are described and include antigenic proteins and proteoglycans derived from N. meningitidis.Type: GrantFiled: April 12, 2010Date of Patent: April 6, 2021Assignee: Secretary of State for Health and Social CareInventors: Andrew Robinson, Margaret Robinson, Andrew Richard Gorringe, Michael John Hudson, Karen Margaret Reddin
-
Publication number: 20210003572Abstract: The present invention provides a method for detecting viral infection of a subject by a first Flavivirus species, said method comprising: (a) contacting a sample from said subject with a solid phase support, wherein said solid phase support includes a capture means for immobilising antibody present in the sample that binds a first antigen from a first Flavivirus species; (b) challenging said immobilised antibody with: (i) a second antigen from a second (different) Flavivirus species, wherein the binding of said second antigen thereto suppresses (e.g.Type: ApplicationFiled: November 23, 2018Publication date: January 7, 2021Applicant: SECRETARY OF STATE FOR HEALTH AND SOCIAL CAREInventors: Richard Tedder, Steven Dicks
-
Patent number: 10646559Abstract: The present invention provides antigens, for use in the treatment or prevention of C. burnetii infection. Also provided are nucleic acids encoding such antigens, and antibodies raised against such antigens.Type: GrantFiled: September 23, 2016Date of Patent: May 12, 2020Assignee: SECRETARY OF STATE FOR HEALTH AND SOCIAL CAREInventors: Julia Vipond, Kevin Bewley
-
Patent number: 10640507Abstract: The invention relates to pyrrolobenzodiazepines compounds (PBDs) and to pharmaceutically acceptable salts thereof, which are useful as medicaments, in particular, to treat bacterial infections.Type: GrantFiled: December 9, 2016Date of Patent: May 5, 2020Assignees: King's College London, Secretary of State for Health and Social CareInventors: Khondaker Mirazur Rahman, John Mark Sutton, Pietro Picconi